L&G
BIOT.L
IE00BF0H7608
L&G Pharma Breakthrough UCITS ETF
Loading chart...

About this ETF

The L&G Pharma Breakthrough UCITS ETF seeks to track the Solactive Pharma Breakthrough Value index. The Solactive Pharma Breakthrough Value index tracks companies involved in the development and manufacturing of so-called "orphan drugs". Orphan drugs are drugs that target very rare diseases.

TER
0.49%

Total Expense Ratio per year

Fund Size
€19.28M

Assets under management

Holdings
41

Underlying equities

Dividend Yield
0%

Accumulating

Fundamentals & Estimates

Weighted valuation multiples and analyst forecasts

Valuation Multiples
Weighted P/E
16.84
Weighted Fwd P/E
20.34
💰 Revenue Estimates
Current Year CY
+23.63% ⌀ 14 Analysts Coverage
Next Year NY
+13.72% ⌀ 14 Analysts Coverage
📈 EPS Estimates (Earnings Per Share)
Current Year CY
-40.13% ⌀ 11 Analysts Coverage
Next Year NY
+237.06% ⌀ 11 Analysts Coverage

Related ETFs

iShares
HEAL.L • iShares
iShares Healthcare Innovation UCITS ETF
10.74 USD
TER 0.4% 1Y +26.8%
ARK
ARXK.DE • ARK
ARK Innovation UCITS ETF
8.9 EUR
TER 0.75% 1Y +13.8%
L&G
DOCT.L • L&G
L&G Healthcare Technology & Innovation UCITS ETF
18.14 USD
TER 0.49% 1Y +37.1%
ARK
AAKG.DE • ARK
ARK Genomic Revolution UCITS ETF
8.64 EUR
TER 0.75% 1Y +79.5%
Xtrackers
GTIS.DE • Xtrackers
Xtrackers World Small Cap Green Tech Innovators UCITS ETF 1C
39.04 EUR
TER 0.45% 1Y +24.6%
VanEck
IE000B9PQW54.SG • VanEck
VanEck Genomics and Healthcare Innovators UCITS ETF
24.67 EUR
TER 0.35%
Xtrackers
GTIL.DE • Xtrackers
Xtrackers World Green Tech Innovators UCITS ETF 1C
35.22 EUR
TER 0.35% 1Y +16.6%
Xtrackers
XGEN.L • Xtrackers
Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C
42.35 USD
TER 0.3% 1Y +68.6%
ETF Profile
Provider
L&G
L&G
Fund Type
ETF
Inception Date
01/23/2018 (8 yrs)
Region
World
Country
-
Strategy
-
Distribution Policy
Accumulating
Replication
Full replication
Sustainable
No

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

5/7 Elevated
17/100 Low (Concentration Risk)
Diversification Score
17/100 Low (Concentration Risk)
5Y Volatility
18.8% p.a.
Max Drawdown (5Y)
-33.6%
Sharpe Ratio (5Y)
-0.01
Beta Factor
0.65
Notes & Warnings
Fund Volume (AUM) ⚠️ Fund closure risk (< 50M € AUM)
⚠️ Fund closure risk (< 50M € AUM)
🟡 Moderate analyst coverage (10.8 analysts)
🔴 Severe sector concentration risk: 98% in "Healthcare".
🔴 Extreme industry concentration: 63% in "Biotechnology".
⚠️ Elevated Regulatory & Policy Risk: 98% in heavily regulated industries (defense, regulated utilities, healthcare policy).
ende